****Published June 2019****

MarketVIEW: *Lyme Borreliosis* vaccines (CAT: VAMV024)

Product Name	:	**MarketVIEW: *Lyme Borreliosis* vaccines**
Description	:	*Lyme Borreliosis* vaccines: global market forecast and size
Contents	:	Executive presentation (~210 slides .pdf) + 1 MS Excel workbook (.xls)
Therapeutic Area	:	New endemic vaccines
Publication date	:	June 2019
Catalogue No	:	VAMV024

Background

***Lyme Borreliosis* (LB)**, or **Lyme disease** is caused by an infection with the bacterial spirochete *Borrelia* genospecies. The pathogen is transmitted to humans through the bite of infected Ixodes tick species. LB, which is endemic in large areas of Europe and North America, can cause a wide range of disease symptoms which range from a mild treatable rash (erythema migrans, EM) to serious multistage complications of the neurological (neuroborreliosis) and musculoskeletal systems. Aside from increased awareness and testing, experts believe the incidence of LB is increasing partly due to expanding vector populations. There are an estimated 300,000 cases of Lyme disease annually each in the US and EU.[1] The disease is significantly underreported and has high profile chronic implications for many individuals.

GSK Biologicals licensed an OspA-based recombinant vaccine **(LYMErix)** in 1998 which was later withdrawn due to several reasons. Both **Baxter Vaccines** and **Sanofi Pasteur** were developing OspA-based approaches, but development was halted. **Valneva** appear to have the only human Lyme Disease vaccine in development (VLA15) which is advancing to Phase II studies. There are many drivers to vaccine development but also controversies and challenges.

This **MarketVIEW** product is composed of a comprehensive Executive summary presentation (~210 slides, .pdf) + MS Excel-based model which forecasts the potential commercial value of a putative *Lyme Borreliosis* vaccines across **27** major Western markets to 2040[2]. Both adult and pediatric, as well as risk-persons,are considered with 3 pricing scenarios (LO, BASE and HI). A detailed review of disease background and epidemiology is included along with current treatment, unmet needs and rationale for vaccine approach with a review of the latest key working group viewpoints. **Target Product Profiles (TPP)** are defined based on recent R&D understanding, along with commercial model assumptions. This analysis is ideally suited to any organisation wishing to understand and justify new investment into this highly important opportunity.

[1] Based on the 24 EU countries surveyed in this study
[2] United States, Canada, Major 5 EU, Other EU – 27 countries in total

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 813155 e-mail: info@vaczine-analytics.com

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to ***Lyme Borreliosis*** epidemiology, hospital in-patient datasets, vaccine development, competitive environment, recommendations, policy. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings, news articles, expert comment etc.

PRODUCT CONTENTS:
Published June 2019 (CAT No: VAMV024)

****This product is a summary presentation (.pdf), a forecast model (.xls)

Contents – Summary presentation (.pdf)[3]

Contents
Author's notes
Executive summary
[SECTION 1] *Lyme Borreliosis* vaccines: key commercial model outputs
[SECTION 2] *Lyme Borreliosis*: disease background
[SECTION 3] *Lyme Borreliosis*: disease epidemiology (US+EU), economic burden
[SECTION 4] *Lyme Borreliosis*: vaccine history and development
[SECTION 5] *Lyme Borreliosis*: estimating vaccine commercial potential
[SECTION 6] *Lyme Borreliosis*: detailed country epidemiological profiles
Bibliography (217 references)
Disclaimer

PAGES: ~210 slides fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Worksheets = >50 interconnected

[3] Full contents i.e. title per slide is proprietary and only available upon valid request

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 813155 e-mail: info@vaczine-analytics.com

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT (All deliverables) - USD **$9,995**/ GBP **£7,800**[#] (Region license)*

[#] Indicative company rate only. Prevailing rate applied to the date of transaction.
*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to the final invoice total
Agency/consultancy rates (commercial use) are available upon request

HOW TO ORDER:

To order, please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased online. Please review the **TERMS and CONDITIONS** of purchase.

BIBLIOGRAPHY

.

~217 references are included in this study

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 813155 e-mail: info@vaczine-analytics.com

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as "The Company"). (Herein [enter client name] to as "The Client").

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (a division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased online invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **$USD dollars, or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees, and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics
of division of Assay Advantage Ltd
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 813155
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website www.vacZine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 813155 e-mail: info@vaczine-analytics.com